Skip to content
Pharma Observatory a Scientist.com platform

Condition (MeSH)

Demyelinating Autoimmune Diseases, CNS

ClinicalTrials.gov lists 3,681 trials for Demyelinating Autoimmune Diseases, CNS or a narrower condition beneath it. Biogen has the most among industry and government lead sponsors, with 160.

MeSH D020278 Nervous System Diseases C10 C20
Email me this page as a PDF

Search trials, drugs, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Phase 1 Phase 1 239 Phase 1/2 Phase 1/2 113 Phase 2 Phase 2 345 Phase 2/3 Phase 2/3 52 Phase 3 Phase 3 289 Phase 4 Phase 4 226 Not applicable Not applicable 1,321 Observational Observational 1,091 Phase 1 Phase 1 239 Phase 1/2 Phase 1/2 113 Phase 2 Phase 2 345 Phase 2/3 Phase 2/3 52 Phase 3 Phase 3 289 Phase 4 Phase 4 226 Not applicable Not applicable 1,321 Observational Observational 1,091

Trials per phase (log scale)

1 more section with rows

24 of the 3,681 trials are tagged with Demyelinating Autoimmune Diseases, CNS itself; the rest are tagged with a narrower condition beneath it.

Get the Demyelinating Autoimmune Diseases, CNS report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

When did Demyelinating Autoimmune Diseases, CNS trials start? (36)

Shown in this order: most recent first, 1990 onwards. 2026 is partial: trials registered with a 2026 start date so far, not a full year. 6 trials are registered to start in 2027 or later, and not listed here.

Trials over time, by phase

  • Phase 1
  • Phase 1/2
  • Phase 2
  • Phase 2/3
  • Phase 3
  • Phase 4
  • Not applicable
  • Observational

Top of scale: 256

1991: 2 trials (Not applicable 1, Phase 3 1) 1992: 1 trials (Observational 1) 1993: 1 trials (Phase 3 1) 1994: 1 trials (Phase 4 1) 1995: 3 trials (Observational 1, Phase 3 1, Phase 1 1) 1996: 2 trials (Observational 2) 1997: 2 trials (Phase 2 1, Phase 1 1) 1998: 3 trials (Phase 2 1, Phase 1/2 1, Phase 1 1) 1999: 11 trials (Observational 1, Phase 4 2, Phase 3 3, Phase 2 4, Phase 1/2 1) 2000: 2 trials (Observational 2) 2001: 18 trials (Not applicable 1, Phase 4 3, Phase 3 5, Phase 2/3 1, Phase 2 5, Phase 1/2 1, Phase 1 2) 2002: 25 trials (Observational 3, Phase 4 2, Phase 3 10, Phase 2 7, Phase 1/2 3) 2003: 41 trials (Observational 6, Not applicable 3, Phase 4 8, Phase 3 5, Phase 2 12, Phase 1/2 3, Phase 1 4) 2004: 40 trials (Observational 8, Not applicable 3, Phase 4 10, Phase 3 3, Phase 2/3 5, Phase 2 7, Phase 1/2 2, Phase 1 2) 2005: 51 trials (Observational 10, Not applicable 5, Phase 4 4, Phase 3 14, Phase 2/3 1, Phase 2 13, Phase 1/2 1, Phase 1 3) 2006: 70 trials (Observational 14, Not applicable 10, Phase 4 5, Phase 3 18, Phase 2/3 1, Phase 2 15, Phase 1/2 4, Phase 1 3) 2007: 70 trials (Observational 20, Not applicable 7, Phase 4 4, Phase 3 15, Phase 2/3 3, Phase 2 14, Phase 1/2 2, Phase 1 5) 2008: 79 trials (Observational 26, Not applicable 6, Phase 4 9, Phase 3 15, Phase 2/3 1, Phase 2 11, Phase 1/2 4, Phase 1 7) 2009: 88 trials (Observational 22, Not applicable 14, Phase 4 7, Phase 3 9, Phase 2/3 4, Phase 2 18, Phase 1/2 5, Phase 1 9) 2010: 110 trials (Observational 28, Not applicable 16, Phase 4 9, Phase 3 14, Phase 2/3 2, Phase 2 20, Phase 1/2 8, Phase 1 13) 2011: 106 trials (Observational 30, Not applicable 24, Phase 4 12, Phase 3 11, Phase 2/3 4, Phase 2 16, Phase 1/2 3, Phase 1 6) 2012: 131 trials (Observational 47, Not applicable 30, Phase 4 13, Phase 3 9, Phase 2/3 3, Phase 2 15, Phase 1/2 6, Phase 1 8) 2013: 144 trials (Observational 32, Not applicable 41, Phase 4 18, Phase 3 14, Phase 2/3 2, Phase 2 17, Phase 1/2 10, Phase 1 10) 2014: 165 trials (Observational 42, Not applicable 60, Phase 4 17, Phase 3 12, Phase 2/3 1, Phase 2 15, Phase 1/2 7, Phase 1 11) 2015: 158 trials (Observational 41, Not applicable 49, Phase 4 16, Phase 3 12, Phase 2/3 4, Phase 2 15, Phase 1/2 6, Phase 1 15) 2016: 142 trials (Observational 36, Not applicable 60, Phase 4 11, Phase 3 10, Phase 2/3 1, Phase 2 12, Phase 1/2 1, Phase 1 11) 2017: 167 trials (Observational 49, Not applicable 71, Phase 4 11, Phase 3 10, Phase 2/3 4, Phase 2 8, Phase 1/2 6, Phase 1 8) 2018: 197 trials (Observational 56, Not applicable 97, Phase 4 5, Phase 3 14, Phase 2 13, Phase 1/2 3, Phase 1 9) 2019: 217 trials (Observational 69, Not applicable 95, Phase 4 8, Phase 3 16, Phase 2/3 2, Phase 2 11, Phase 1/2 4, Phase 1 12) 2020: 206 trials (Observational 69, Not applicable 90, Phase 4 9, Phase 3 12, Phase 2/3 4, Phase 2 6, Phase 1/2 4, Phase 1 12) 2021: 255 trials (Observational 106, Not applicable 93, Phase 4 11, Phase 3 8, Phase 2/3 3, Phase 2 16, Phase 1/2 3, Phase 1 15) 2022: 212 trials (Observational 71, Not applicable 90, Phase 4 8, Phase 3 13, Phase 2/3 4, Phase 2 15, Phase 1/2 5, Phase 1 6) 2023: 256 trials (Observational 81, Not applicable 138, Phase 4 5, Phase 3 8, Phase 2 11, Phase 1/2 3, Phase 1 10) 2024: 229 trials (Observational 77, Not applicable 107, Phase 4 5, Phase 3 4, Phase 2/3 2, Phase 2 13, Phase 1/2 3, Phase 1 18) 2025: 222 trials (Observational 58, Not applicable 114, Phase 4 5, Phase 3 8, Phase 2 16, Phase 1/2 5, Phase 1 16)

Trials registered with a start date in each year, 1990 onward, stacked by phase (complete years only; the current partial year is in the table's notes). The table below lists the same counts, most recent years first.

Trials started per year
Year Trials started
2026 (partial year) 229
2025 222
2024 229
2023 256
2022 212
2021 255
2020 206
2019 217
2018 197
2017 167

Showing 10 of 36 earlier years.

Start your 14-day trial Email me all 36 earlier years as a PDF

Forecast of the full-year count, planned starts included, not rows of this table: about 260 trials starting in 2026 and about 240 in 2027, the average of the 24 months through September, counted as registered and carried forward. The rows of this table count trials registered so far with a start date in the year, planned starts included; the forecast looks ahead to the count for the whole year, so it is not the same measure. In backtests on conditions of this size, forecasts made part-way through the year were typically off by about 13 percent and ran about 12 percent low against the count later registered; forecasts made before the year began were off by about 19 percent and ran about 17 percent low against the count later registered, and had about the same error as repeating last year's count. These figures rest on a few years of history (target years from 2018 to 2025, varying by figure), place each condition as it is mapped today rather than as it was then, and score against a count for the newest year that was still being revised. Only condition series were scored.

Prediction, not a registry value: median of 36 months from start to primary completion across 330 trials still running at the 2026-10-09 snapshot; registered median of 22 months across 2,298 trials with a primary completion typed Actual. Source: ClinicalTrials.gov / AACT (CTTI), public domain.

What phase are Demyelinating Autoimmune Diseases, CNS trials in? (9)

Shown in this order: phase order.

Show the trials by phase as a table
Trials by phase
Phase Trials
Phase 1 239
Phase 1/2 113
Phase 2 345
Phase 2/3 52
Phase 3 289
Phase 4 226
Not applicable 1,321
Observational 1,091
Expanded access 5

How many Demyelinating Autoimmune Diseases, CNS trials are recruiting? (12)

Shown in this order: the order a trial moves through, from not yet recruiting to unknown.

Trials by recruitment status
Status Trials
Not yet recruiting 169
Recruiting 403
Enrolling by invitation 50
Active, not recruiting 162
Available 1

Showing 5 of 12 statuses.

Start your 14-day trial Email me all 12 statuses as a PDF

Status as registered on ClinicalTrials.gov. Each trial is counted once.

Which lead sponsors run the most Demyelinating Autoimmune Diseases, CNS trials? (7)

Shown in this order: most trials first. Lead sponsors the registry classes as industry, NIH, US federal, other government or network. A hospital or university the registry files as government can appear here. Sponsors it classes as academic or other are shown on the full page, because that class cannot separate an institution from a named investigator.

Lead sponsors
Sponsor Trials
Biogen 160
Novartis Pharmaceuticals 92
Merck KGaA, Darmstadt, Germany 49
Bayer 47
Hoffmann-La Roche 39

Showing 5 of 7 sponsors.

Start your 14-day trial Email me all 7 sponsors as a PDF

Which drugs are being tested for Demyelinating Autoimmune Diseases, CNS? (3)

Shown in this order: most trials first. One row per drug, matched to a single molecule under all its names, ranked by number of trials.

Drugs tested
Drug Trials
Dimethyl Fumarate 60
METHYLPREDNISOLONE 43
RITUXIMAB 26

Interventions as named in the registry (12)

Shown in this order: most trials first.

Interventions as named in the registry
Drug Trials
SC interferon beta-1a 80
Ocrelizumab SC 72
fingolimob (FTY) 55
SC interferon beta-1b 50
natalizumab SC 49

Showing 5 of 12 interventions.

Start your 14-day trial Email me all 12 interventions as a PDF

These are the names sponsors entered on ClinicalTrials.gov that we have not matched to a single molecule. Some are drugs under a brand or code name; others are procedures, doses or arm labels.

Which serious adverse events do Demyelinating Autoimmune Diseases, CNS trials report? (10)

Shown in this order: most subjects affected first. Subjects affected summed across trials, a cross-trial signal, not a rate.

Serious adverse events in this condition's trials
Adverse event Subjects affected Trials
Multiple sclerosis relapse 1,787 88
Multiple Sclerosis Relapse 664 29
Urinary tract infection 412 84
Pneumonia 367 99
MULTIPLE SCLEROSIS RELAPSE 282 12

Showing 5 of 10 adverse events.

Start your 14-day trial Email me all 10 adverse events as a PDF

Which publications cover Demyelinating Autoimmune Diseases, CNS? (15)

Shown in this order: major-topic papers first, then newest, then most linked to trials.

Publications
Publication Journal Year Major topic
Chinese neuroimmunological disease (NIDBase) cohort study: cohort profile. BMJ open 2026 Yes
Myelin-oligodendrocyte glycoprotein antibody-associated disease. The Lancet. Neurology 2021 Yes
The clinical features of combined central and peripheral demyelination in Chinese patients. Journal of neuroimmunology 2018 Yes
New clinical implications of anti-myelin oligodendrocyte glycoprotein antibodies in children with CNS demyelinating diseases. Multiple sclerosis and related disorders 2018 Yes
The gut microbiome in human neurological disease: A review. Annals of neurology 2017 Yes

Showing 5 of 15 publications.

Start your 14-day trial Email me all 15 publications as a PDF

Sub-conditions in MeSH (7)

MeSH descendants one level down with at least one trial, most trials first.

Not on this page

Not measured: delivery record.

Checked, with nothing recorded for this condition: prevalence and rare-disease identity.

Browse all condition evidence pages